S&P 500   3,117.72 (+0.16%)
DOW   27,685.95 (+0.13%)
QQQ   202.72 (+0.14%)
AAPL   265.44 (+1.41%)
FB   199.21 (+0.25%)
MSFT   149.99 (+0.09%)
GOOGL   1,324.03 (+0.39%)
AMZN   1,744.38 (-0.93%)
CGC   18.61 (+1.25%)
NVDA   208.72 (-0.33%)
MU   46.56 (+0.56%)
BABA   200.15 (+3.31%)
GE   10.80 (-1.01%)
TSLA   331.23 (-0.54%)
T   38.22 (+0.32%)
AMD   39.68 (-0.05%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.68 (+1.12%)
NFLX   302.76 (-0.51%)
BAC   33.19 (+0.12%)
GILD   66.01 (-1.11%)
DIS   148.10 (-0.12%)
S&P 500   3,117.72 (+0.16%)
DOW   27,685.95 (+0.13%)
QQQ   202.72 (+0.14%)
AAPL   265.44 (+1.41%)
FB   199.21 (+0.25%)
MSFT   149.99 (+0.09%)
GOOGL   1,324.03 (+0.39%)
AMZN   1,744.38 (-0.93%)
CGC   18.61 (+1.25%)
NVDA   208.72 (-0.33%)
MU   46.56 (+0.56%)
BABA   200.15 (+3.31%)
GE   10.80 (-1.01%)
TSLA   331.23 (-0.54%)
T   38.22 (+0.32%)
AMD   39.68 (-0.05%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.68 (+1.12%)
NFLX   302.76 (-0.51%)
BAC   33.19 (+0.12%)
GILD   66.01 (-1.11%)
DIS   148.10 (-0.12%)
S&P 500   3,117.72 (+0.16%)
DOW   27,685.95 (+0.13%)
QQQ   202.72 (+0.14%)
AAPL   265.44 (+1.41%)
FB   199.21 (+0.25%)
MSFT   149.99 (+0.09%)
GOOGL   1,324.03 (+0.39%)
AMZN   1,744.38 (-0.93%)
CGC   18.61 (+1.25%)
NVDA   208.72 (-0.33%)
MU   46.56 (+0.56%)
BABA   200.15 (+3.31%)
GE   10.80 (-1.01%)
TSLA   331.23 (-0.54%)
T   38.22 (+0.32%)
AMD   39.68 (-0.05%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.68 (+1.12%)
NFLX   302.76 (-0.51%)
BAC   33.19 (+0.12%)
GILD   66.01 (-1.11%)
DIS   148.10 (-0.12%)
S&P 500   3,117.72 (+0.16%)
DOW   27,685.95 (+0.13%)
QQQ   202.72 (+0.14%)
AAPL   265.44 (+1.41%)
FB   199.21 (+0.25%)
MSFT   149.99 (+0.09%)
GOOGL   1,324.03 (+0.39%)
AMZN   1,744.38 (-0.93%)
CGC   18.61 (+1.25%)
NVDA   208.72 (-0.33%)
MU   46.56 (+0.56%)
BABA   200.15 (+3.31%)
GE   10.80 (-1.01%)
TSLA   331.23 (-0.54%)
T   38.22 (+0.32%)
AMD   39.68 (-0.05%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.68 (+1.12%)
NFLX   302.76 (-0.51%)
BAC   33.19 (+0.12%)
GILD   66.01 (-1.11%)
DIS   148.10 (-0.12%)
Log in

NASDAQ:NURO - Neurometrix Stock Price, Forecast & News

$4.63
-0.36 (-7.21 %)
(As of 12/5/2019 03:27 PM ET)
Today's Range
$4.51
Now: $4.63
$5.14
50-Day Range
$0.26
MA: $1.53
$5.15
52-Week Range
$2.52
Now: $4.63
$13.80
Volume3,355 shs
Average Volume21,195 shs
Market Capitalization$4.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 million
Cash Flow$0.24 per share
Book Value$7.93 per share

Profitability

Net Income$20,000.00

Miscellaneous

Employees42
Market Cap$4.53 million
Next Earnings Date1/23/2020 (Estimated)
OptionableNot Optionable

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.


Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix shares reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) posted its quarterly earnings data on Thursday, October, 17th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The medical device company had revenue of $2.09 million for the quarter, compared to analysts' expectations of $3.94 million. Neurometrix had a negative return on equity of 65.19% and a negative net margin of 48.86%. View Neurometrix's Earnings History.

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for Neurometrix.

What price target have analysts set for NURO?

1 equities research analysts have issued 1 year price objectives for Neurometrix's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's stock price to reach $5.00 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for Neurometrix.

What is the consensus analysts' recommendation for Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.

Has Neurometrix been receiving favorable news coverage?

Headlines about NURO stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurometrix earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Neurometrix.

Are investors shorting Neurometrix?

Neurometrix saw a increase in short interest in November. As of November 15th, there was short interest totalling 142,300 shares, an increase of 20.5% from the October 31st total of 118,100 shares. Based on an average trading volume of 118,300 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are short sold. View Neurometrix's Current Options Chain.

Who are some of Neurometrix's key competitors?

What other stocks do shareholders of Neurometrix own?

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
  • Dr. Xuan Kong Ph.D., Chief Data Scientist

Who are Neurometrix's major shareholders?

Neurometrix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (95.33%). Company insiders that own Neurometrix stock include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Institutional Ownership Trends for Neurometrix.

Which major investors are buying Neurometrix stock?

NURO stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Neurometrix stock in the last two years include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Insider Buying and Selling for Neurometrix.

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $4.63.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $4.53 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe.View Additional Information About Neurometrix.

What is Neurometrix's official website?

The official website for Neurometrix is http://www.neurometrix.com/.

How can I contact Neurometrix?

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]


MarketBeat Community Rating for Neurometrix (NASDAQ NURO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel